Want to see BBIO full AI Analyst Report?
Top Page
BridgeBio Pharma
(NASDAQ:BBIO)
Select Model
Select Model
Rating:59Neutral
Price Target:
$88.00
▲(4.74% Upside)
Action:Reiterated
Date:08/11/26
The score is held back primarily by weak financial performance (large losses, significant cash burn, and negative equity), partially offset by strong earnings-call-driven momentum (multiple NDA reviews, accelerating Attruby commercialization, and improved funding runway) and a constructive technical setup with the stock trending above major moving averages. Valuation support is limited due to negative earnings and no dividend yield.
Positive Factors
Attruby commercial growth and high gross margin
Rapid Attruby adoption provides an expanding commercial revenue base, while very high gross margins support attractive product economics. Sustained uptake and payer access could increasingly offset development costs as the company scales its marketed business.
Negative Factors
Large operating losses and persistent cash burn
BridgeBio remains far from self-funded operations despite growing revenue. Continued cash consumption increases execution pressure and means the company must achieve launch success, expand margins, or secure further capital before durable cash generation is established.
Read all positive and negative factors
Positive Factors
Negative Factors
Attruby commercial growth and high gross margin
Rapid Attruby adoption provides an expanding commercial revenue base, while very high gross margins support attractive product economics. Sustained uptake and payer access could increasingly offset development costs as the company scales its marketed business.
Read all positive factors
BridgeBio Pharma Key Performance Indicators (KPIs)
Any
Revenue by Segment
Highlights how much revenue each business segment generates, providing insight into which areas are driving growth and which may need strategic adjustments.
Highlights how much revenue each business segment generates, providing insight into which areas are driving growth and which may need strategic adjustments.
Data provided by:
The Fly
The FlyBridgeBio Pharma (BBIO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$16.41B
Dividend YieldN/A
Average Volume (3M)4.02M
Price to Earnings (P/E)―
Beta (1Y)0.68
Revenue Growth202.39%
EPS Growth12.83%
CountryUS
Employees839
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.58
Shares Outstanding195,487,470
10 Day Avg. Volume2,133,765
30 Day Avg. Volume4,019,845
Financial Highlights & Ratios
PEG Ratio-0.64
Price to Book (P/B)-7.27
Price to Sales (P/S)30.05
P/FCF Ratio-33.75
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$108.56Price Target Upside29.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
EPS Forecast (FY)-2.23
Revenue Forecast (FY)$1.01B
BridgeBio Pharma Business Overview & Revenue Model
Company Description
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning...
How the Company Makes Money
BridgeBio makes money primarily through (1) product sales from its commercial medicines and (2) collaboration-related income typical of biopharma companies.
1) Product sales (commercial revenue)
- BridgeBio generates revenue from the sale of its ...
BridgeBio Pharma Earnings Call Summary
Earnings Call Date:Aug 10, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Oct 29, 2026
Earnings Call Sentiment Positive
The call emphasized strong commercial execution and meaningful clinical differentiation for Attruby (notably new kidney protection data and multiple supportive RWE analyses), substantial pipeline progress with three NDAs under review and clear commercial readiness, and a fortified balance sheet following a $1.0B preferred equity raise. Offsetting these positives were the disappointing CARDIO-TTRansform result (undermining combination therapy), higher operating expenses to fund multiple launches, and some revenue mix/one-time revenue headwinds. On balance, the company portrayed momentum across commercial, clinical, and financial fronts with manageable near-term risks tied to execution, upcoming regulatory decisions, and competitive/payer dynamics.Positive Updates
Strong Revenue Growth Driven by Attruby
Net product revenue for Attruby was $222.4M in Q2 2026 vs $71.5M in Q2 2025, an increase of $150.9M; total company revenues were $243.7M vs $110.6M a year ago (+$133.1M). Attruby delivered another quarter with >$35M sequential U.S. revenue growth and was described as the fastest-growing brand in the space at ~23%.
Negative Updates
CARDIO-TTRansform Failed to Meet Primary Endpoint
CARDIO-TTRansform (eplontersen + stabilizer) did not meet its primary efficacy endpoint; combination therapy showed no added benefit over stabilizer monotherapy, representing a setback for the concept of combination treatment and reinforcing stabilizers as first-line therapy.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong Revenue Growth Driven by Attruby
Net product revenue for Attruby was $222.4M in Q2 2026 vs $71.5M in Q2 2025, an increase of $150.9M; total company revenues were $243.7M vs $110.6M a year ago (+$133.1M). Attruby delivered another quarter with >$35M sequential U.S. revenue growth and was described as the fastest-growing brand in the space at ~23%.
Read all positive updates
Company Guidance
BridgeBio laid out specific near‑term regulatory and commercial milestones and financials: three NDAs are in review (BBP‑418 accepted May 27, 2026 with PDUFA Nov 27, 2026, priority review; encaleret accepted July 22, 2026 with PDUFA May 8, 2027 and MAA filed July 27, 2026; infigratinib NDA submitted with MAA targeted Q4 and potential approval mid‑2027), they expect three launches over the next 12 months and commercial impact for Attruby within ~6–9 months, a RECLAIM‑HP Phase 3 readout in ~18 months, and further pipeline activity (targeting ~5 INDs by year‑end and ~8 PoC readouts in 2027–28); Q2 metrics included Attruby net product revenue of $222.4M (vs. $71.5M YoY, a $150.9M increase), total revenue $243.7M (vs. $110.6M), BEYONTTRA royalties ~$15.4M, sequential Attruby sales increases >$35M, operating expenses $335.7M (vs. $241.2M, +$94.5M), loss from operations $107.1M (improved ~20% YoY from $134.3M), gross‑to‑net guided at 30–40%, Attruby growth cited at 23% with market growth 19% this quarter (51% YoY), cash of $720.2M at 6/30/26 plus a $1.0B preferred equity closed 7/1/26 (bringing cash to ~ $1.7B) to fund the launches, and an expectation to reach breakeven/cash‑generating profitability in the 2027 timeframe.BridgeBio Pharma Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
22
Negative
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 691.84M | 502.08M | 221.90M | 9.30M | 77.65M | 69.72M |
| Gross Profit | 644.38M | 473.81M | 218.02M | 6.86M | 74.21M | 66.60M |
| EBITDA | -602.77M | -672.88M | -436.83M | -565.47M | -397.44M | -533.83M |
| Net Income | -696.24M | -729.31M | -535.76M | -643.20M | -481.18M | -562.54M |
Balance Sheet | ||||||
| Total Assets | 1.22B | 936.02M | 919.34M | 546.38M | 623.04M | 1.01B |
| Cash, Cash Equivalents and Short-Term Investments | 720.16M | 587.48M | 681.10M | 434.88M | 471.92M | 836.66M |
| Total Debt | 2.49B | 2.73B | 1.73B | 1.74B | 1.72B | 1.73B |
| Total Liabilities | 3.72B | 3.01B | 2.38B | 1.89B | 1.87B | 1.88B |
| Stockholders Equity | -2.52B | -2.08B | -1.47B | -1.35B | -1.25B | -870.41M |
Cash Flow | ||||||
| Free Cash Flow | -592.12M | -447.01M | -521.66M | -529.03M | -425.81M | -546.18M |
| Operating Cash Flow | -586.61M | -445.91M | -520.73M | -527.72M | -419.49M | -497.93M |
| Investing Cash Flow | -34.14M | -24.49M | 60.78M | 54.03M | 453.15M | -200.83M |
| Financing Cash Flow | 247.36M | 359.29M | 748.46M | 451.54M | -13.13M | 736.45M |
BridgeBio Pharma Technical Analysis
Positive
84.02
Price Trends
78.39
Positive
74.42
Positive
73.08
Positive
Market Momentum
0.88
Positive
54.30
Neutral
45.45
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BBIO, the sentiment is Positive. The current price of 84.02 is above the 20-day moving average (MA) of 82.69, above the 50-day MA of 78.39, and above the 200-day MA of 73.08, indicating a bullish trend. The MACD of 0.88 indicates Positive momentum. The RSI at 54.30 is Neutral, neither overbought nor oversold. The STOCH value of 45.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BBIO.
BridgeBio Pharma Risk Analysis
BridgeBio Pharma disclosed 102 risk factors in its most recent earnings report. BridgeBio Pharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BridgeBio Pharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $13.48B | 16.32 | 42.49% | ― | 9.23% | 53.08% | |
70 Outperform | $13.42B | 178.11 | 1.18% | ― | 13.69% | -89.03% | |
59 Neutral | $16.41B | -23.17 | 31.67% | ― | 202.39% | 12.83% | |
55 Neutral | $69.62B | -16.71 | -39.20% | ― | -27.62% | -6.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $10.10B | -16.98 | -110.84% | ― | -7.49% | -98.12% | |
47 Neutral | $12.48B | -40.27 | -56.65% | ― | 149.04% | -0.28% |
* Healthcare Sector Average
BBIO
BridgeBio Pharma
82.94
33.86
68.99%
BMRN
BioMarin Pharmaceutical
67.68
9.10
15.53%
EXEL
Exelixis
53.69
15.06
38.99%
IONS
Ionis Pharmaceuticals
58.76
16.07
37.64%
MDGL
Madrigal Pharmaceuticals
519.09
104.41
25.18%
MRNA
Moderna
133.32
106.20
391.59%
BridgeBio Pharma Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
BridgeBio Pharma announces major secondary share offering
Neutral
Aug 17, 2026
On August 13, 2026, BridgeBio Pharma, Inc. and selling stockholder KKR Genetic Disorder L.P. agreed with underwriters led by William Blair, Goldman Sachs and KKR Capital Markets to conduct a secondary offering of 5,000,000 shares of BridgeBio comm...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
BridgeBio’s Encaleret NDA Accepted by U.S. FDA
Positive
Jul 22, 2026
On July 22, 2026, BridgeBio announced that the U.S. Food and Drug Administration accepted its New Drug Application for encaleret to treat autosomal dominant hypocalcemia type 1, assigning a Prescription Drug User Fee Act target action date of May ...
Business Operations and StrategyPrivate Placements and Financing
BridgeBio Raises $934 Million via Preferred Equity Financing
Positive
Jul 2, 2026
On July 1, 2026, BridgeBio Pharma entered into an investment agreement with funds managed by Sixth Street and HealthCare Royalty for a $933.9 million issuance of Series A Cumulative Convertible Participating Preferred Stock, with Sixth Street cont...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
BridgeBio shareholders approve board changes and equity plan
Positive
Jun 26, 2026
On June 22, 2026, BridgeBio Pharma held its annual meeting of stockholders, at which director Randal W. Scott resigned from the board upon completion of his term as a Class I director, with the company stating his departure did not stem from any d...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
BridgeBio Wins FDA Priority Review for BBP-418 Therapy
Positive
May 27, 2026
On May 27, 2026, BridgeBio Pharma announced that the U.S. Food and Drug Administration accepted and granted Priority Review to its New Drug Application for oral BBP-418 to treat limb-girdle muscular dystrophy type 2I/R9, with a Prescription Drug U...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.